{"id":"oams","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OAMs (Oral Antidiabetic Medications) is a broad category rather than a single drug entity. Eli Lilly's phase 3 OAM candidates typically include agents targeting insulin secretion, insulin sensitivity, or glucose metabolism. Without a specific compound identifier, the exact mechanism cannot be precisely defined, but Lilly's pipeline in this space includes GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors.","oneSentence":"OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:46.409Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04809220","phase":"PHASE3","title":"A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":591},{"nctId":"NCT04613765","phase":"","title":"A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting","status":"UNKNOWN","sponsor":"Jules Bordet Institute","startDate":"2020-12-01","conditions":"Adults, Hematological Malignancy, Oral Antineoplastic Agents","enrollment":113},{"nctId":"NCT01894568","phase":"PHASE3","title":"A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":388},{"nctId":"NCT01582451","phase":"PHASE3","title":"A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":466},{"nctId":"NCT01435616","phase":"PHASE3","title":"A Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":1538},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT00664534","phase":"PHASE4","title":"Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OAMs","genericName":"OAMs","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OAMs are oral antidiabetic agents that work through multiple mechanisms to improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}